{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:57:18Z","timestamp":1785542238610,"version":"3.56.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofpsychiatricresearch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jpsychires.2017.06.004","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T04:47:16Z","timestamp":1497415636000},"page":"23-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Buprenorphine augmentation improved symptoms of OCD, compared to placebo - Results from a randomized, double-blind and placebo-controlled clinical trial"],"prefix":"10.1016","volume":"94","author":[{"given":"Mohammad","family":"Ahmadpanah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Reihani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ghaleiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Soltanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Haghighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Jahangard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1301-5522","authenticated-orcid":false,"given":"Dena","family":"Sadeghi Bahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Holsboer-Trachsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2017.06.004_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders 5th Edition: DSM 5","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.jpsychires.2017.06.004_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-clinpsy-021815-093533","article-title":"The efficacy of exposure therapy for anxiety-related disorders and its underlying mechanisms: the case of OCD and PTSD","volume":"12","author":"Foa","year":"2016","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.jpsychires.2017.06.004_bib3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1176\/ajp.156.4.660a","article-title":"Rapid remission of OCD with tramadol hydrochloride","volume":"156","author":"Goldsmith","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.004_bib4","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.004_bib5","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euroneuro.2015.11.008","article-title":"New treatment models for compulsive disorders","volume":"26","author":"Grant","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2017.06.004_bib6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)","volume":"228","author":"Haghighi","year":"2013","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.jpsychires.2017.06.004_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jpsychires.2015.06.020","article-title":"Repetitive Transcranial Magnetic Stimulation (rTMS) improves symptoms and reduces clinical illness in patients suffering from OCD\u2013Results from a single-blind, randomized clinical trial with sham cross-over condition","volume":"68","author":"Haghighi","year":"2015","journal-title":"J.\u00a0psychiatric Res."},{"key":"10.1016\/j.jpsychires.2017.06.004_bib8","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2017.2200","article-title":"Obsessive-compulsive disorder: advances in diagnosis and treatment","volume":"317","author":"Hirschtritt","year":"2017","journal-title":"JAMA"},{"issue":"Suppl 5","key":"10.1016\/j.jpsychires.2017.06.004_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004850-199612005-00007","article-title":"Obsessive-compulsive disorder-related disorders: the role of selective serotonergic reuptake inhibitors","volume":"11","author":"Hollander","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2017.06.004_bib10","doi-asserted-by":"crossref","DOI":"10.1159\/000446287","article-title":"Repetitive Transcranial Magnetic Stimulation (rTMS) improved symptoms of obsessive compulsive disorders (OCD), but also cognitive performance? \u2013 Results from randomized clinical trial with cross-over design and sham-condition","author":"Jahangard","year":"2016","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jpsychires.2017.06.004_bib11","series-title":"British National Formulary (BNF)","author":"Joint Formula Committee","year":"2004"},{"key":"10.1016\/j.jpsychires.2017.06.004_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4088\/JCP.v66n0312","article-title":"Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder","volume":"66","author":"Koran","year":"2005","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.004_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2045125312462233","article-title":"Buprenorphine augmentation in the treatment of refractory obsessive-compulsive disorder","volume":"3","author":"Liddell","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2017.06.004_bib14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","article-title":"Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines","volume":"30","author":"Pallanti","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.004_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-006-0619-5","article-title":"Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A\/C) receptor-mediated behavior","volume":"190","author":"Rojas-Corrales","year":"2007","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.jpsychires.2017.06.004_bib16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/da.22232","article-title":"Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials","volume":"31","author":"Romanelli","year":"2014","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.jpsychires.2017.06.004_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the national comorbidity survey replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.004_bib18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/(SICI)1520-6394(1997)6:4<170::AID-DA7>3.0.CO;2-G","article-title":"Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder","volume":"6","author":"Shapira","year":"1997","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.jpsychires.2017.06.004_bib19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/070674379704200624","article-title":"A\u00a0possible new treatment approach to obsessive-compulsive disorder","volume":"42","author":"Warneke","year":"1997","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.004_bib20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.pbb.2011.10.007","article-title":"The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder","volume":"100","author":"Wu","year":"2012","journal-title":"Pharmacol. Biochem. Behav."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395617305216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395617305216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T17:07:43Z","timestamp":1659114463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395617305216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":20,"alternative-id":["S0022395617305216"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2017.06.004","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine augmentation improved symptoms of OCD, compared to placebo - Results from a randomized, double-blind and placebo-controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2017.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}